Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-11
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1486127040-2d871407d82744269fa20ef56224f5ef.jpg "Where Can You Buy Netspend Cards?")
:max_bytes(150000):strip_icc():format(jpeg)/ABeginnersGuidetoCallBuying-e0433db389da44ebb6dee9682d72e612.jpg "A Beginner’s Guide to Call Buying")
